# Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01194258` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01194258](<https://clinicaltrials.gov/study/NCT01194258>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01194258

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 132 participants.

## Technical summary

Registry record NCT01194258. Randomized; quadruple masking; primary purpose treatment. Start 2010-08 (registry gives no type); primary completion 2011-08 (actual). Results posted on 2014-08-20.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 132 participants (enrolled count; ClinicalTrials.gov record NCT01194258, source copy `cardio:ctgov-nct01194258-2014-08-20`, retrieved 2026-10-26)
- Start date: 2010-08 (registry gives no type) (ClinicalTrials.gov record NCT01194258, source copy `cardio:ctgov-nct01194258-2014-08-20`, retrieved 2026-10-26)
- Primary completion: 2011-08 (actual) (ClinicalTrials.gov record NCT01194258, source copy `cardio:ctgov-nct01194258-2014-08-20`, retrieved 2026-10-26)
- Completion: 2011-08 (actual) (ClinicalTrials.gov record NCT01194258, source copy `cardio:ctgov-nct01194258-2014-08-20`, retrieved 2026-10-26)
- Results first posted: 2014-08-20 (ClinicalTrials.gov record NCT01194258, source copy `cardio:ctgov-nct01194258-2014-08-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT01194258, source copy `cardio:ctgov-nct01194258-2014-08-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01194258-2014-08-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Patients With Type 2 Diabetes Mellitus
- Condition: Diabetes Mellitus, Type II
- Intervention (Drug): Insulin lispro
- Intervention (Drug): Insulin aspart
- Intervention (Drug): Recombinant human hyaluronidase PH20
- Intervention (Drug): Insulin glulisine
- Intervention (Drug): Insulin glargine
- Lead sponsor: Halozyme Therapeutics
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: af7c2e184f1447daf230844fd78c69e9594ccca3df05db72dc315443049cef72
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
